Drug Discovery Featured Articles & Applications

  1. Datapoints Summit 2026 Highlights: Moving AI Closer To The Lab 9/22/2026

    At the Datapoints Summit, speakers showed where AI can improve drug discovery—and why better data, validation, and scientific judgment remain essential for lasting progress.

  2. Can An Ibogaine Analog Preserve The Therapeutic Potential Without The Trip Or Cardiac Risk? 9/17/2026

    Ibogaine’s anecdotal and clinical signals on cravings, withdrawal, and PTSD are growing, but the biggest obstacle is that ibogaine carries serious cardiac risk and hallucinations.

  3. Viewing Treatment Resistance As A Target 9/16/2026

    Viewing treatment resistance as a target instead of an undesirable side effect could allow effective treatments to work for longer.

  4. Wall Street Is Wary Of NAMs — And For Good Reason: What Happens To Yesterday's Drugs? 9/15/2026

    Part 2 follows the consequences into Wall Street, asking what better evidence could mean for pharmaceutical valuations and, ultimately, drugs already in the portfolio.

  5. What I Heard When NAMs Became a Conversation, Not a Webinar 9/11/2026

    The AAPS/BioIVT interactive event made NAM adoption feel less like a science debate and more like a trust-building exercise rooted in use cases, standards, and candid exchange.

  6. Using Low-Intensity Focused Ultrasound To Open The Blood–Brain Barrier 9/11/2026

    We caught up with Davinder Ramsingh, MD, to talk about the potential of using low-intensity focused ultrasound (LIFU) to open the blood–brain barrier.

  7. Wall Street Is Wary Of NAMs — And For Good Reason: The Evidentiary Shift 9/10/2026

    Part I of this series focuses on the evidentiary shift of how NAMs may change the architecture of evidence and how that transition unfolds.

  8. Measuring Cellular Water Content As A New Tool For Organoid Characterization 9/9/2026

    A collaboration between MIT, KAIST, and Dana Farber Cancer Institute created a technology that, for the first time, quantifies water content in single organoids.

  9. Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases 9/4/2026

    Targeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition. 

  10. Moving Beyond The mRNA Momentum: The Preclinical Path To Personalized Scalable Solid Tumor Immunotherapies 9/3/2026

    Translating early momentum into accessible, scalable therapies for refractory solid tumors requires prioritizing multitargeted off-the-shelf platforms at the preclinical stage.